Is Biogen Inc. a Buy?

Biogen's stock has had an awful 2018 so far. Is this top biotech now an incredible bargain?

What's Biogen's Big Risk?

The company's facing an increasingly competitive market for its best-selling drugs.

Is Biogen a Risky Stock?

Industry Focus' crew tries to figure out whether Biogen will reward investors in 2017.

2016's Worst Clinical Failures

It's been a rough year for drugmakers, but late clinical-stage failures made it especially tough ...

3 Reasons to Sell Biogen

Increasing competition within the multiple sclerosis market makes Biogen king of a crumbling empi...